Description
Advances have led to the production of new radiopharmaceuticals and availability of new production routes. Various new diagnostic agents in the field (such as Ga-68 radiopharmaceuticals and generators) as well as therapeutic agents (such as alpha emitters) have been added to the clinician’s menu. It is essential that radiopharmaceuticals are prepared within a robust quality control system encompassing materials and personnel, with adequate documentation, and continuous review of ongoing results. This publication provides guidelines and best practices for the quality control of medical radioisotopes and radiopharmaceuticals. It was written by a group of experts with experience across a range of radiopharmaceuticals and is intended to support professionals in the preparation of good quality and safe products to be used in nuclear medicine procedures.
More Information on reusing IAEA copyright material.
Keywords
Nuclear Medicine, Radiopharmaceuticals, Pharmaceutical Industry, Quality Control, Radioisotopes in Pharmacology, Radionuclides, Best Practices, Medical Radioisotopes, Production, Member States, Validation, Equipment, Instruments, Techniques, Protocols, Legislation, Training, Personnel, Quality Control Assays, Diagnosis, Therapeutic Applications, Methods, Countries, Regions, North America, South America, Asia, Russia, Quality Assurance, Gamma Spectrometry, Starting Materials, Radiochemical Purity, Chemical Purity, Osmolality, Dose, Chromatography, Method Qualification, Testing, Safety Considerations, Out of Specification, GMP, Good Manufacturing Practice, Radionuclidic Purity, SOP, Standard Operating Procedures, Specific Activity, Therapeutic Agents
Related publications
2024
2024
2023
2023
2023
2023
2023
2023
2022
2022
2022
2022
2022
2021
2021
2021
2021
2021